Loomis, Sayles & Company
IDXX icon

Loomis, Sayles & Company’s Idexx Laboratories IDXX Stock Holding History

Loomis, Sayles & Company’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30
Closed -$17K – 827
2023
Q4 		$17K Sell
30
-8
-21% -$3.76K ﹤0.01% 703
2023
Q3 		$17K Buy
+38
New +$18.9K ﹤0.01% 708
2023
Q1 		– Sell
-36
Closed -$15K – 1002
2022
Q4 		$15K Sell
36
-5
-12% -$1.94K ﹤0.01% 756
2022
Q3 		$13K Buy
41
+5
+14% +$1.84K ﹤0.01% 652
2022
Q2 		$13K Buy
36
+31
+620% +$12.6K ﹤0.01% 630
2022
Q1 		$3K Buy
+5
New +$2.63K ﹤0.01% 870
2021
Q4 		– Sell
-16
Closed -$10K – 833
2021
Q3 		$10K Buy
+16
New +$10.8K ﹤0.01% 808
2021
Q2 		– Sell
-26
Closed -$13K – 870
2021
Q1 		$13K Hold
26
– – ﹤0.01% 723
2020
Q4 		$13K Buy
+26
New +$11.6K ﹤0.01% 678

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Loomis, Sayles & Company's IDXX Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Idexx Laboratories (IDXX) in Q1 2024, closing a stake of 30 shares — an estimated $17K sold.

Loomis, Sayles & Company first reported a position in IDXX in Q4 2020 and held it in 9 quarters. The position peaked at $17K in Q4 2023. 1,149 funds tracked by Wall St. Rank hold IDXX as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Idexx Laboratories position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 30 Idexx Laboratories shares in Q1 2024, an estimated $17K.
  • Loomis, Sayles & Company first reported a position in Idexx Laboratories in Q4 2020 and held it in 9 quarters.
  • Loomis, Sayles & Company's Idexx Laboratories position peaked at $17K in Q4 2023.
  • 1,149 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.